Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Department of Plastic, Reconstructive and Aesthetic Surgery, Istanbul, Turkey.
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Department of Plastic, Reconstructive and Aesthetic Surgery, Istanbul, Turkey.
Int J Infect Dis. 2020 Dec;101:29-32. doi: 10.1016/j.ijid.2020.09.1466. Epub 2020 Sep 30.
Coronavirus-triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named COVID-19, and ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition prompted us to search the related literature to show a potential target (COX2) and a weapon (celecoxib). The concept of selectively targeting COX2 and closely related cascades might be worth trying in the treatment of COVID-19 given the substantial amount of data showing that COX2, p38 MAPK, IL-1b, IL-6 and TGF-β play pivotal roles in coronavirus-related cell death, cytokine storm and pulmonary interstitial fibrosis. Considering the lack of definitive treatment and importance of immunomodulation in COVID-19, COX2 inhibition might be a valuable adjunct to still-evolving treatment strategies. Celecoxib has properties that should be evaluated in randomized controlled studies and is also available for off-label use.
冠状病毒引发的肺部和全身性疾病，即病毒引发的肺部损伤引起的全身炎症反应，被命名为 COVID-19，目前正在讨论如何在不抑制 COX2 的情况下对 COVID-19 进行免疫调节，这促使我们检索相关文献，以寻找一个潜在的靶点（COX2）和一种武器（塞来昔布）。鉴于大量数据表明 COX2、p38MAPK、IL-1b、IL-6 和 TGF-β 在冠状病毒相关的细胞死亡、细胞因子风暴和肺间质纤维化中发挥关键作用，选择性靶向 COX2 及其相关级联的概念在治疗 COVID-19 方面可能值得一试。鉴于缺乏明确的治疗方法和 COVID-19 中免疫调节的重要性，COX2 抑制可能是仍在不断发展的治疗策略的有益补充。塞来昔布具有在随机对照研究中进行评估的特性，也可用于标签外使用。
